BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 28589527)

  • 1. Targeting the Tumor Stroma: the Biology and Clinical Development of Pegylated Recombinant Human Hyaluronidase (PEGPH20).
    Wong KM; Horton KJ; Coveler AL; Hingorani SR; Harris WP
    Curr Oncol Rep; 2017 Jul; 19(7):47. PubMed ID: 28589527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer.
    Jacobetz MA; Chan DS; Neesse A; Bapiro TE; Cook N; Frese KK; Feig C; Nakagawa T; Caldwell ME; Zecchini HI; Lolkema MP; Jiang P; Kultti A; Thompson CB; Maneval DC; Jodrell DI; Frost GI; Shepard HM; Skepper JN; Tuveson DA
    Gut; 2013 Jan; 62(1):112-20. PubMed ID: 22466618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer.
    Hingorani SR; Harris WP; Beck JT; Berdov BA; Wagner SA; Pshevlotsky EM; Tjulandin SA; Gladkov OA; Holcombe RF; Korn R; Raghunand N; Dychter S; Jiang P; Shepard HM; Devoe CE
    Clin Cancer Res; 2016 Jun; 22(12):2848-54. PubMed ID: 26813359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic Contrast-enhanced MRI Detects Responses to Stroma-directed Therapy in Mouse Models of Pancreatic Ductal Adenocarcinoma.
    Cao J; Pickup S; Clendenin C; Blouw B; Choi H; Kang D; Rosen M; O'Dwyer PJ; Zhou R
    Clin Cancer Res; 2019 Apr; 25(7):2314-2322. PubMed ID: 30587546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.
    Provenzano PP; Cuevas C; Chang AE; Goel VK; Von Hoff DD; Hingorani SR
    Cancer Cell; 2012 Mar; 21(3):418-29. PubMed ID: 22439937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual Stromal Targeting Sensitizes Pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy.
    Blair AB; Wang J; Davelaar J; Baker A; Li K; Niu N; Wang J; Shao Y; Funes V; Li P; Pachter JA; Maneval DC; Dezem F; Plummer J; Chan KS; Gong J; Hendifar AE; Pandol SJ; Burkhart R; Zhang Y; Zheng L; Osipov A
    Gastroenterology; 2022 Nov; 163(5):1267-1280.e7. PubMed ID: 35718227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer.
    Doherty GJ; Tempero M; Corrie PG
    Future Oncol; 2018 Jan; 14(1):13-22. PubMed ID: 29235360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PEGPH20, a PEGylated human hyaluronidase, induces radiosensitization by reoxygenation in pancreatic cancer xenografts. A molecular imaging study.
    Seki T; Saida Y; Kishimoto S; Lee J; Otowa Y; Yamamoto K; Chandramouli GV; Devasahayam N; Mitchell JB; Krishna MC; Brender JR
    Neoplasia; 2022 Aug; 30():100793. PubMed ID: 35523073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models.
    Thompson CB; Shepard HM; O'Connor PM; Kadhim S; Jiang P; Osgood RJ; Bookbinder LH; Li X; Sugarman BJ; Connor RJ; Nadjsombati S; Frost GI
    Mol Cancer Ther; 2010 Nov; 9(11):3052-64. PubMed ID: 20978165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models.
    Morosi L; Meroni M; Ubezio P; Fuso Nerini I; Minoli L; Porcu L; Panini N; Colombo M; Blouw B; Kang DW; Davoli E; Zucchetti M; D'Incalci M; Frapolli R
    J Exp Clin Cancer Res; 2021 Sep; 40(1):286. PubMed ID: 34507591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform.
    Ko AH; Kim KP; Siveke JT; Lopez CD; Lacy J; O'Reilly EM; Macarulla T; Manji GA; Lee J; Ajani J; Alsina Maqueda M; Rha SY; Lau J; Al-Sakaff N; Allen S; Lu D; Shemesh CS; Gan X; Cha E; Oh DY
    Oncologist; 2023 Jun; 28(6):553-e472. PubMed ID: 36940261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the Stromal Pro-Tumoral Hyaluronan-CD44 Pathway in Pancreatic Cancer.
    Koltai T; Reshkin SJ; Carvalho TMA; Cardone RA
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depolymerization of hyaluronan using PEGylated human recombinant hyaluronidase promotes nanoparticle tumor penetration.
    Brundel DH; Feeney OM; Nowell CJ; Suys EJ; Gracia G; Kaminskas LM; McIntosh MM; Kang DW; Porter CJ
    Nanomedicine (Lond); 2021 Feb; 16(4):275-292. PubMed ID: 33560142
    [No Abstract]   [Full Text] [Related]  

  • 14. Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors.
    Manuel ER; Chen J; D'Apuzzo M; Lampa MG; Kaltcheva TI; Thompson CB; Ludwig T; Chung V; Diamond DJ
    Cancer Immunol Res; 2015 Sep; 3(9):1096-107. PubMed ID: 26134178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-Invasive Monitoring of Stromal Biophysics with Targeted Depletion of Hyaluronan in Pancreatic Ductal Adenocarcinoma.
    Maloney E; DuFort CC; Provenzano PP; Farr N; Carlson MA; Vohra R; Park J; Hingorani SR; Lee D
    Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31167451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interstitial Pressure in Pancreatic Ductal Adenocarcinoma Is Dominated by a Gel-Fluid Phase.
    DuFort CC; DelGiorno KE; Carlson MA; Osgood RJ; Zhao C; Huang Z; Thompson CB; Connor RJ; Thanos CD; Scott Brockenbrough J; Provenzano PP; Frost GI; Michael Shepard H; Hingorani SR
    Biophys J; 2016 May; 110(9):2106-19. PubMed ID: 27166818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is hyaluronan deposition in the stroma of pancreatic ductal adenocarcinoma of prognostic significance?
    Gebauer F; Kemper M; Sauter G; Prehm P; Schumacher U
    PLoS One; 2017; 12(6):e0178703. PubMed ID: 28582436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression.
    Li X; Shepard HM; Cowell JA; Zhao C; Osgood RJ; Rosengren S; Blouw B; Garrovillo SA; Pagel MD; Whatcott CJ; Han H; Von Hoff DD; Taverna DM; LaBarre MJ; Maneval DC; Thompson CB
    Clin Cancer Res; 2018 Oct; 24(19):4798-4807. PubMed ID: 30084839
    [No Abstract]   [Full Text] [Related]  

  • 19. Breaching the Castle Walls: Hyaluronan Depletion as a Therapeutic Approach to Cancer Therapy.
    Shepard HM
    Front Oncol; 2015; 5():192. PubMed ID: 26380222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on phase I studies in advanced pancreatic adenocarcinoma. Hunting in darkness?
    Strimpakos AS; Saif MW
    JOP; 2013 Jul; 14(4):354-8. PubMed ID: 23846926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.